This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

clascoterone in acne vulgaris

Authoring team

Clascoterone in acne vulgaris

  • clascoterone (cortexolone 17α-propionate) 1% cream is a first-in-class topical steroidal androgen receptor antagonist approved for the topical treatment of acne vulgaris in patients aged 12 years and older
  • unlike systemic antiandrogen therapies (such as combined oral contraceptives or spironolactone), which are restricted or unsuitable in males due to systemic hormonal adverse effects, clascoterone acts locally and is approved for use in both male and female patients

Mechanism of action

  • competitive androgen blockade: clascoterone competes directly with dihydrotestosterone (DHT) for binding to cutaneous androgen receptors within sebaceous glands, sebocytes, and hair follicles
  • downstream effects: inhibition of androgen receptor signalling reduces androgen-mediated transcription of genes driving sebocyte proliferation, lipogenesis (sebum production), and pro-inflammatory cytokine release
  • local inactivation: following topical application, clascoterone is rapidly metabolised in the skin to cortexolone (an inactive metabolite with weak glucocorticoid activity), minimising systemic exposure (<1% excreted in urine) and preventing systemic antiandrogenic effects

Clinical efficacy

  • phase 3 clinical trials: pooled analysis of two 12-week, double-blind, vehicle-controlled phase 3 trials (n=1,421; patients aged 12 years with moderate to severe facial acne) demonstrated statistically significant superiority of twice-daily clascoterone 1% cream over vehicle:
    • Investigator's Global Assessment (IGA) treatment success (score of 0 or 1 with 2-grade improvement): 19.9% vs 7.7% ()
    • non-inflammatory lesion count reduction: -20.8 vs -11.9 (-30.8% vs -18.3%; )
    • inflammatory lesion count reduction: -19.7 vs -14.0 (-46.2% vs -32.5%; )
  • durability and sex independence: efficacy is comparable across male and female patients and is sustained - with continued improvement - in open-label extension studies lasting up to 9 to 12 months
  • therapeutic positioning: while indirect network meta-analyses suggest comparable efficacy to certain topical retinoids, direct head-to-head trials against established first-line agents (such as topical retinoids or benzoyl peroxide) are lacking; clascoterone can be used as monotherapy or alongside topical retinoids, benzoyl peroxide, antibiotics, or oral isotretinoin

Administration and practical considerations

  • application: apply a thin layer twice daily (morning and evening) to clean, dry acne-prone skin; avoid application to cuts, abrasions, sunburn, or eczematous skin, and wash hands before and after use
  • storage: store refrigerated prior to dispensing and discard 6 months after the dispensing date

Adverse effects, contraindications, and precautions

  • common local reactions: generally mild and similar in frequency to vehicle, including erythema, scaling or dryness, pruritus, stinging or burning, oedema, and skin atrophy
  • rare paradoxical and atypical reactions: isolated case reports have documented severe paradoxical nodulocystic acne flares (requiring immediate discontinuation) and perioral dermatitis
  • hypothalamic-pituitary-adrenal (HPA) axis suppression: transient, reversible subclinical HPA axis suppression (resolving within 4 weeks of cessation) has been observed under maximum-use conditions (3 times the recommended daily dose); exercise caution if applied over large surface areas, for prolonged periods, or under occlusive dressings
  • systemic laboratory monitoring: does not cause clinically significant hyperkalaemia or QT interval prolongation; routine blood or electrolyte monitoring is not required
  • pregnancy and lactation: contraindicated in pregnancy (teratogenicity and embryofetal death observed in animal studies); no data are available regarding safety during breastfeeding

References:

  1. Shefa S, Szwach J, Karwowska A, Wojno A, Łyko M. Clascoterone in the Treatment of Acne Vulgaris: A Narrative Review. Pharmaceuticals. 2026;19(8):1304.
  2. Australian Prescriber. New drugs: Clascoterone for acne. Aust Prescr. 2024;47(5):160-161.
  3. Logreira Castillo A, Amaya Muñoz MC, Castillo Garavito SJ, Rojas Lopez RF. Severe acne induced by clascoterone: A case report. JAAD Case Rep. 2026;70:264-266.

Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page